Crossmark

NIRO or No-go? Positioning a Novel Systemic Treatment Option for Desmoid Tumours

Published Online: 2023-03-12

Published Print: 2023-05

Authors

Loong, Herbert H.

Gupta, Abha

Gronchi, Alessandro https://orcid.org/0000-0002-4703-3534
License Information

Text and Data Mining valid from 2023-03-12

Version of Record valid from 2023-03-12
More Information

Article History

Received: 6 November 2022

Accepted: 12 November 2022

First Online: 12 March 2023

Disclosures

: Alessandro Gronchi: Compensation for advisory boards from SpringWorks. Compensation for advisory boards from Novartis, Pfizer, Bayer, PharmaMar, Lilly, Deciphera. Institutional research grants from PharmaMar.

Free to read: This content has been made available to all.

Document is current